JAN 31, 2019 6:00 AM PST

Overcoming Challenges in EuCODE Cell Culture Platform Development

Presented at: BioProcessing 2019
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Principal Scientist, Ambrx
    Biography
      Weimin Lin earned a MD from Peking University Health Science Center which is the medical school of Peking University, and, a PhD from Georgia State University in cellular physiology program. After graduation, she joined Kinetic BioSystem Inc. and then KBI BioPharma which is a spin-out company of Kinetic Biosystems Inc., focusing on bioprocess development and clinical GMP manufacturing. In 2008, she joined Biogen cell culture development department pilot plant group and established small scale group in 2011 at RTP site. Currently, she is the principal scientist in cell culture development department at Ambrx. She leads the PD team to develop and optimize Ambrx unique EuCODE™ Cell Culture Platform including chemically-defined media, cell culture bioprocessing systems and biomanufacturing process modeling.

    Abstract

    Ambrx’s mammalian expression platform (EuCODE™) enables non-native amino acids (nnAAs) through an expanded genetic code to both generate novel bio-therapeutics and to optimize the performance of antibody drug conjugate (ADC), therapeutic proteins, monoclonal antibodies (mAbs), and, bi- and multi-specific medicines. While the ability to control the defined Drug-to-Antibody Ratio (DAR) and payload site can provide an advantage to an ADC, the site-specific incorporation of the nnAAs into the antibody heavy chain introduces a unique challenge for antibody production.

    To enable higher performance benchmarks in time and resources for process development with stringent product quality requirements, a proprietary cell culture platform is being developed and demonstrated fast-track development of high-quality, high-titer processes for producing recombinant proteins from CHO cells. 

    We successfully generated a CHO-K1 cell line, stably expressing engineered amber suppressor tRNA and its cognate tRNA synthetase specific for nnAA para-acetyl phenylalanine (pAF), to achieve high production of monoclonal antibodies (mAbs) containing nnAAs. The stable cell lines were further evolved using CRISPR/Cas9 genome editing technology to sequentially knock out selected genes in glutamine synthesis, and, apoptosis pathways to improve selection efficiency and prevent loss of viable cell mass in production cultures, respectively.  Inhibition of apoptosis pathway leads to dramatic increase in viable cell mass and results in extended production time and increased productivity. 

    In this presentation, we will discuss overcoming the challenges in cell culture platform development including cell line engineering, systematic DoE-based approaches on optimal chemically defined media and cell culture processes, and, strategies for scale up to clinical and commercial scales.

    Learning Objectives: 

    1. Learn what is cell culture platform and how to development your own cell culture platform
    2. Learn the strategy to develop your own chemically-defined media


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    JUN 23, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    DEC 10, 2019 9:00 AM PST
    C.E. CREDITS
    DEC 10, 2019 9:00 AM PST
    DATE: December 10, 2019TIME: 9:00am PST, 12:00pm EST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid dif...
    Loading Comments...
    Show Resources
    Attendees
    • See more